system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND AND AIM, METHODS AND RESULTS. Meshes: Apolipoprotein A-I, Apolipoproteins B, Blood Glucose, Cholesterol, Cholesterol, HDL, Cholesterol, LDL, Diabetes Mellitus, Type 2, Female, Gliclazide, Glycated Hemoglobin A, Humans, Insulin, Lipids, Lipoprotein(a), Lipoproteins, Male, Reference Values, Sulfonylurea Compounds, Triglycerides.
user
Lipid and lipoprotein patterns in type 2 non-obese diabetic patients. Do Lp(a) levels decrease with improved glycemic control in these patients? Context: In this study, we investigated the levels of apolipopotein-AI (apo-AI), apolipoprotein (apo-B), triglyceride (TG), high-density-lipoprotein-cholesterol (HDL-C), low-density-lipoprotein-cholesterol (LDL-C), total cholesterol, lipoprotein(a) in a group of non-obese, type 2 diabetes mellitus patients with different types of treatment and a control group of non-obese, non-diabetic subjects. Patients were divided into three groups according to their treatment types: insulin, sulphonylurea and untreated groups. All groups were similar in sex, weights, known duration of diabetes and habits. Each group consisted of 30 subjects. There were no differences in apo-AI, apo-B and TG levels (p>0.05), whereas HDL-C levels in the untreated group were significantly lower than those of the other groups (p<0.05). Lp(a) levels in the untreated group were higher than in the other (p<0.05).
assistant
Gaining metabolic control in diabetes mellitus is crucial in pulling back lipid, lipoprotein and apolipoprotein levels to a desired level and in attenuating CAD (coronary artery disease) risk factors, and also in preventing CAD. Lp(a) levels in particular are decreased by insulin or sulfonylurea in non-obese patients with type 2 diabetes mellitus.